Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No Near-Term Separations For Pfizer, But Business Model Will “Evolve”

This article was originally published in The Pink Sheet Daily

Executive Summary

Beyond the sale of its nutritionals business and spin-out of animal health into Zoetis, no additional separations are planned for Pfizer in the near-term. But CEO Ian Read discussed how he sees the company’s Established Products and Emerging Markets businesses evolving over the long-term, including the potential for an eventual breakout, during a year-end financial call Jan. 29.


Related Content

The Specter Of Spin-off Plans Dominates Pfizer Year-end Earnings
Deals Of The Week: Pfizer Management Updates Thoughts On Split
Pfizer’s Prevnar 13 Is Approved For Older Children As Use In Adults Lags
AbbVie Sets Out To Win Over Investors In Its First Financial Call
Eliquis Label Looks Great, But May Leave Door Open For Pradaxa To Compete On Efficacy
Pfizer Moo’ved To Split Off Zoetis Business By July 2013
Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B
Pfizer: Established Products And Consumer Health In; Animal Health And Nutrition Out
Pfizer To Buy King Pharma For $3.6 billion In Order to Strengthen Pain Franchise


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts